{"product_id":"hla-dra1-antibody-sc-f2822","title":"HLA DR + DP + DQ Antibody","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eHLA-DRA1 is a target of interest in many antibody-based workflows. HLA DR + DP + DQ are the three major isotypes of human MHC class II molecules, essential for presenting extracellular antigenic peptides to CD4+ T cells and mediating immune responses, including thymic selection. Structurally, each is composed of a polymorphic α and β chain forming a peptide-binding heterodimer, with high variability enabling diverse antigen presentation. Depending on the literature source, HLA-DRA1 may also be discussed as HLA DR + DP + DQ and HLA-DRA.\u003c\/p\u003e\u003cp\u003eReported cellular context includes cell membrane, endoplasmic reticulum, endosome, and golgi apparatus, which can matter when signal is compared across treatments or changing cell states. Following HLA-DRA1 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state. In practice, this target is often considered at the family or isoform-group level, so experimental interpretation benefits from matched controls and clear comparison logic.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eHLA-DRA1 is commonly interpreted in the context of immunology and infectious disease research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell membrane, endoplasmic reticulum, and endosome, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.\u003c\/p\u003e\u003cp\u003eConsider these angles when interpreting target-level changes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eapparent redistribution between cell membrane, endoplasmic reticulum, and endosome across matched conditions\u003c\/li\u003e\n\u003cli\u003econtext differences tied to immune-cell state, activation, or lineage composition\u003c\/li\u003e\n\u003cli\u003ehost-response changes during infection or pathogen-associated stimulation\u003c\/li\u003e\n\u003cli\u003eco-patterning with orthogonal markers and control conditions that clarify pathway state\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVariant Considerations\u003c\/h2\u003e\u003cp\u003eIf your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for HLA-DRA1. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.\u003c\/p\u003e\u003cp\u003eStandardize sampling time, control choice, and downstream analysis thresholds so apparent differences in HLA-DRA1 reflect biology rather than handling. When interpreting HLA-DRA1, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.\u003c\/p\u003e\u003cp\u003eFor multi-run studies, a shared reference condition can keep HLA-DRA1 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"20 µl","offer_id":57577974038873,"sku":"F2822-20UL","price":199.0,"currency_code":"EUR","in_stock":true},{"title":"100 µl","offer_id":57577974071641,"sku":"F2822-100UL","price":489.0,"currency_code":"EUR","in_stock":true},{"title":"2 × 100 µl","offer_id":57577974104409,"sku":"F2822-2X100UL","price":729.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/absource.de\/products\/hla-dra1-antibody-sc-f2822","provider":"Absource Diagnostics","version":"1.0","type":"link"}